Gene therapy: models to study the immunological way.
Gene engineering to enhance tumour immunogenicity and elicit curative responses against established tumours and tumour recurrences has become an attractive prospect. Gene engineering enables new genes to be selectively inserted into the genome of a tumour cell, or the construction of new fusion plasmids coding tumour antigens and immunomodulatory molecules. The rationale behind current research is to enhance the immune recognition of tumour antigens through their association with the molecules on which immune recognition depends. The immunotherapy data obtained in many experimental tumour systems provide a realistic assessment of the potential and limits of this technological approach. Experimental vaccination of rodents has been shown to induce a significant immune memory, even against poorly immunogenic tumours, that can prevent tumour growth and cure initial metastases, but is poorly effective against established tumours. Its use in tumour prevention is a fresh dawning perspective.
Forni
G
G
Department of Clinical and Biology Sciences, University of Turin, Orbassano, Italy.
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D000951:Antigens, Neoplasm / Q000276:immunology; D016207:Cytokines / Q000235:genetics; D005805:Genes, MHC Class I; D005818:Genetic Engineering; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D014161:Transduction, Genetic
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D016207:Cytokines